Document:

Prepared by R.R. Donnelley Financial -- EX-10.2

 Exhibit 10.2 

 
 

 
  

 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan 

Phone +81-(0)3-3296-3631, Fax +81-(0)3-3296-3681 

January 27, 2014 
 Zosano Pharma, Inc. 

34790 Ardentech Court 
 Fremont, CA 94555 

United States of America 
 Attn: Mr. Vikram Lamba, President
and Chief Executive Officer 
 [Via Express Courier Service / Via Facsimile (Fax +1 510 742 8262)] 

Re: Notice of Termination 
 Ladies
and Gentlemen: 
 Reference is made to the Amended and Restated License Agreement dated as of April 1, 2012, as amended by the First Amendment thereto
dated as of December 14, 2012, by and between Zosano Pharma, Inc. (“Zosano”) and Asahi Kasei Pharma Corporation (“AKP”) (“License Agreement”). 

AKP hereby terminates the License Agreement at will in its entirety pursuant to Section 15.2 of the License Agreement, effective immediately as of the
date of this letter agreement (the “Termination Date”), with the surviving provisions of the License Agreement remaining valid. By its signature below, Zosano hereby waives, in accordance with Section 17.8 of the License Agreement,
the one hundred eighty (180) days’ notice period for termination as provided in Section 15.2 of the License Agreement, and agrees to AKP’s termination of the License Agreement as of the Termination Date. For the avoidance of
doubt, the foregoing waiver shall not be deemed to affect, alter or modify the consequences of termination of the License Agreement as set forth in Section 15.7(d) thereof or the survival of provisions of the License Agreement as set forth in
Section 15.8 thereof. Zosano and AKP may publish the fact of termination of the License Agreement and AKP’s discontinuance of the Development (as defined in the License Agreement), in English and/or in Japanese, with the content of each of
Zosano’s and AKP’s publication to be substantially in the form of the press release attached hereto as Exhibit A. 
 Notwithstanding the
termination of the License Agreement according to the foregoing 

 

 
  

			
	Zosano Pharma, Inc.	  	 January 27, 2014

 Page
 2

  

 
paragraph, Zosano hereby agrees by its signature below, that AKP may, following the Termination Date, perform in accordance with Articles 4 and 9 of the License Agreement, the work concerning
preparation of the reports and other documents relating to the Development activities conducted by AKP during the term of the License Agreement, which is required under Applicable Laws (as defined in the License Agreement) and/or is consistent with
the Development Plan (as defined in the License Agreement) and AKP’s internal past practices in the ordinary course of business, provided that AKP agrees to provide to Zosano a copy of each such report and other document promptly
following its preparation, and such reports and other documents shall be deemed to be Project Information (as defined in the License Agreement) owned by AKP and subject to the licenses granted to Zosano pursuant to Sections 2.2 and 15.7 of the
License Agreement. 
 Without limiting the generality of Section 15.7(d) of the License Agreement and all surviving provisions of the License Agreement
referred to in Section 15.8 thereof, Asahi hereby confirms, and Zosano hereby confirms by its signature below, that: 
  

	(1)	Except payments payable by AKP or AKP USA, Inc. (AKP’s Affiliate (as defined in the License Agreement), “AKPUS”) to Zosano or ZP Group LLC (a wholly owned subsidiary of Zosano, “LLC”) under or
contemplated by the Termination and Membership Interest Transfer Agreement dated as of December 20, 2013, by and among Zosano, LLC, AKPUS and AKP, no other payments are payable by AKP or AKPUS to Zosano, any of Zosano’s Affiliates or LLC
under the License Agreement or any other related agreements; 

  

	(2)	AKP shall destroy all Products (as defined in the License Agreement) and Placebo Patches (as defined in the License Agreement) other than those samples required to be retained by Applicable Laws, received from Zosano or
LLC under the License Agreement or any other related agreements, in compliance with Applicable Laws, and furnish Zosano with a certificate indicating what was destroyed, the amounts (if applicable), and a statement certifying that such Products and
Placebo Patches were disposed in accordance with Applicable Laws; 

  

	(3)	Zosano shall, or shall cause LLC to, destroy all Teribone formulations and its standard solutions received from AKP under the License Agreement or any other related agreements, in compliance with Applicable Laws, and
furnish AKP with a certificate indicating what was destroyed, the amounts (if applicable), and a statement certifying that such Teribone formulations and its standard solutions were disposed in accordance with Applicable Laws; 

 

	(4)	 Zosano shall, and shall cause LLC to, retain samples of the Product Patches (as defined in the License Agreement) and Placebo Patches supplied to AKP
under the License Agreement or any other related agreements until the third (3rd) anniversary of December 17, 2013 (i.e., the date AKP determined discontinuation of the Development of
the 

 

 
  

			
	Zosano Pharma, Inc.	  	 January 27, 2014

 Page
 3

  

	 	
Product), in accordance with Applicable Laws in Japan and Zosano’s or LLC’s “Retain Products SOP QA-417” (except for the duration of retaining samples). The amount of samples
of such Product Patches and Placebo Patches shall be at least twice the quantity required to carry out all of the tests required to determine whether such Product Patches and Placebo Patches meet its release specifications, with the exception of
bioburden and endotoxin testing; and 

  

	(5)	Zosano shall, and shall cause LLC to, retain samples of the Product Patches and Placebo Patches supplied to Zosano under certain related agreements of the License Agreement (i.e., the Memorandum dated as of
December 14, 2012, as amended by the Amendment No. 1 to Memorandum dated as of February 25, 2013, by and among Zosano, AKP and LLC, and the Quality Agreement dated as of December 14, 2012, by and among Zosano, AKP and LLC), and
all materials thereof, for a certain period in accordance with Applicable Laws in Australia. 

  

			
	Sincerely,
	
	ASAHI KASEI PHARMA CORPORATION
		
	By:	 	 /s/ Toshio Asano

	Name:	 	Toshio Asano
	Title:	 	President
	
	Acknowledged and agreed:
	
	ZOSANO PHARMA, INC.
		
	By:	 	 /s/ Vikram Lamba

	Name:	 	Vikram Lamba
	Title:	 	President and CEO

 Copy to: Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA
94025 
 United States of America 

Attn: Alan C. Mendelson 

          Judith A. Hasko 

(FAX: +1 650 463 2600) 

 

 
  

			
	Zosano Pharma, Inc.	  	 January 27, 2014

 Page
 4

  

 Foley Hoag LLP 

Seaport West 
 155 Seaport
Boulevard, Boston 
 Massachusetts 02210-2600 

United States of America 
 Attn:
Mr. Joel D. Needleman 
 (Fax +1 617 832 7000) 

 EXHIBIT A 

Form of AKP Press Release 

Discontinuation of the development of a transdermal patch formulation of 

TeriboneTM human parathyroid hormone 

Asahi Kasei Pharma Corporation (headquarters: Tokyo, Japan; President: Toshio Asano) and Zosano Pharma, Inc. (headquarters: Fremont, California, USA; CEO:
Vikram Lamba) have reached a decision to discontinue the development of a transdermal patch formulation of TeriboneTM human parathyroid hormone using microprojection technology from Zosano and to terminate the relevant license agreement between
Asahi Kasei Pharma and Zosano. 
 Asahi Kasei Pharma has advanced the development of the transdermal patch formulation in Japan under the license agreement
with Zosano, but results of the Phase I clinical trial did not meet the go/no-go decision criteria established by Asahi Kasei Pharma to proceed to Phase II. It was therefore determined that the development of this formulation could not continue.

 Moving forward, Asahi Kasei Pharma remains committed to further developments of new formulations of TeriboneTM that enhance usability for patients.

  

			
	For more information, please contact:	 	
	Asahi Kasei Pharma Corporation	 	Asahi Kasei Corporation
	General Affairs	 	Corporate Communications
	Phone: +81-(0)3-3296-3600	 	Phone: +81-(0)3-3296-3008
	Fax: +81-(0)3-3296-3680	 	Fax: +81-(0)3-3296-3162Prepared by R.R. Donnelley Financial -- EX-10.3

 Exhibit 10.3 

CONFIDENTIAL 
 February 22, 2011 

Patrick Hannon 
 ALZA Corporation 

700 Eubanks Drive 
 Vacaville, CA 95688 

Re:    Intellectual Property License Agreement dated October 5, 2006 between ALZA Corporation (“ALZA”) and The Macroflux
Corporation (predecessor in interest to Zosano Pharma, Inc.) (the “Agreement”). 
 Dear Mr. Hannon: 

As you know, ALZA and Zosano Pharma, Inc. (“Zosano”) are parties to the Agreement, under which Zosano obtained certain rights to develop products
for the transdermal delivery of active pharmaceutical ingredients based upon the Macroflux® technology. Zosano is negotiating the terms under which Zosano would collaborate with one or more
third parties in the development and commercialization of PTH Products (as defined in the Agreement). As Zosano and ALZA have discussed, Zosano desires to modify the terms set forth in Section 15.7, which govern the ability of Sublicensees (as
defined in the Agreement) to retain the rights sublicensed to them by Zosano upon certain terminations of the Agreement, solely to address the mechanisms under which rights sublicensed to a Sublicensee with respect to PTH Products would survive
termination of the Agreement. This letter amendment (“Letter Amendment”) sets forth the terms under which Zosano and ALZA have agreed to modify Section 15.7 solely with respect to rights a Sublicensee may retain for PTH Products. For
clarity, Section 15.7 shall not be deemed to be modified by this Letter Amendment for purposes of the survival of Sublicensees’ rights to any Products other than PTH Products. Any capitalized terms in this Letter Amendment not otherwise
defined herein shall have the meaning provided in the Agreement. 
 1.    Section 15.7.3 shall be modified as follows solely with
respect to licenses granted to Sublicensees with respect to PTH Products. For clarity, Section 15.7.3 as it appears in the Agreement immediately prior to this Letter Amendment shall continue to apply to sublicenses for all Products other than
PTH Products, and Section 15.7.3 shall be deemed modified as set forth in this Letter Amendment solely for purposes of sublicenses with respect to PTH Products, as set forth below. 

(a)    The phrase “following the First Sale of the second Product” shall be deemed to be omitted from such
Section. 
 (b)    Subsection (iv) shall be deemed to be replaced in its entirety with the following: “(iv)
the royalties and non-royalty payments to ALZA by such Sublicensee in respect of PTH Products will be what ALZA would have received from TMC under this Agreement in respect of such Sublicensee’s activities with respect to PTH Products;”

 (c)    Subsection (v) shall be deemed to be replaced in its entirety with the following: “(v) the
Sublicensee will pay its portion of ALZA’s patent filing, prosecution, issuance 

 CONFIDENTIAL 
  

and maintenance expenses related to those Licensed Patents under which such Sublicensee has been granted a sublicense, and would otherwise have been borne by TMC under Section 7.3.2(a) of
this Agreement, which expenses will be apportioned pro rata among each surviving Sublicensee with respect to the sublicense granted each Sublicensee in each applicable country(ies) or territory(ies); 

(d)    Subsection (vi) shall be deemed to be modified by adding the following to the end of such subsection
immediately prior to the semicolon: “, except that for sublicenses granted for Japan, Korea, Taiwan or China, such Sublicensee shall be obligated under such Sections to use those efforts that would be devoted by a mid-sized Japanese specialty
pharmaceutical company doing business in the relevant country, rather than those that would be devoted by a United States-based, mid-sized, specialty pharmaceutical company’’ 

(e)    The last three sentences of Section 15.7.3 (commencing with the phrase “ALZA may require...”)
shall be deemed to be replaced in their entirety with the following four sentences: 
 “ALZA may require any Sublicensee of rights to
PTH Products that is a party to a sublicense agreement that survives termination of this Agreement pursuant to this Section 15.7.3 to enter into a direct license with ALZA to “replace such sublicense agreement, for the purpose of
clarifying the terms of the rights retained by such Sublicensee following termination of this Agreement. Specifically, such direct license shall be consistent with this Agreement, as modified to the extent necessary to implement the standards set
forth in this Section 15.7.3(c)(i)-(vii) and to reflect the scope of rights granted to such Sublicensee pursuant to the relevant sublicense granted by TMC. If ALZA desires to enter into a direct license with a Sublicensee, ALZA will
provide written notification to such Sublicensee and will, for a period of ninety (90) days after providing such notice, negotiate in good faith the terms and conditions of, and enter into, with such Sublicensee a direct license under the
Licensed Patents, Future ALZA Patents, and ALZA Know-How, in each case, to the extent such rights were sublicensed from TMC to such Sublicensee in the sublicensed field. If ALZA and such Sublicensee do not enter into a direct license within such
ninety (90) day negotiation period, either ALZA or the Sublicensee may submit outstanding any issues for resolution on the terms set forth in Article 17 of this Agreement.” 

2.    Section 1.20 shall be amended to include the following as the last sentence in such section: 

‘‘For clarity, references to ALZA’s licensees in this Section 1.20 are intended to refer to ALZA’s Third Party
licensees, and are not intended, and shall not be deemed, to refer to: (1) licenses between ALZA and its Affiliates; or (2) TMC, its Affiliates or Sublicensees.” 

Except as expressly modified by this Letter Amendment, the Agreement shall continue in full force and effect. This Letter Amendment may be executed in
counterparts, each of which shall be deemed an original, and all of which together shall constitute one legal instrument. 

 CONFIDENTIAL 
  

If the foregoing is acceptable to ALZA, please sign two copies of this Letter Amendment where indicated below and send one copy back to me. 

Please call me if you have any questions. 
  

	
	Sincerely,
	
	/s/ Gail Shulze
	Gail Schulze
	CEO and Executive Chair of the Board
	Zosano Pharma, Inc.

  

	
	Agreed and acknowledged:
	
	/s/ Patrick Hannon
	Patrick Hannon
	President, ALZA Corporation and
	General Manager of GPSG West, a unit of ALZA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]